PRF Preparation: Choukroun Protocol and Clinical Methodology
Platelet-rich fibrin (PRF), developed by Joseph Choukroun in 2001, represents an autologous biomaterial derived from patient blood through standardized centrifugation protocols. The Choukroun protocol involves collection of 10mL venous blood in a sterile glass-coated tube without anticoagulant, followed by immediate centrifugation at 2,700 rotations per minute for 12 minutes in a tabletop centrifuge. The centrifugation process separates blood components based on specific gravity: red blood cells settle inferiorly, acellular plasma rises superiorly, and the intermediate layer containing platelets, fibrin, and leukocytes forms a fibrin clot. This fibrin clot is carefully extracted using sterile tweezers, separating it from the underlying red blood cell layer and superior acellular plasma.
The resulting PRF clot exhibits a three-dimensional fibrin matrix architecture distinct from platelet-poor fibrin (PPF) formed in serum, characterized by tight organization of platelet-embedded fibrin fibers. The matrix provides both structural support and a biological reservoir of growth factors due to the enmeshment of platelets and leukocytes within the fibrin scaffold. The preparation process is critically dependent on centrifugation parameters; variations in relative centrifugal force (RCF), duration, or rotor speed significantly alter the quality and growth factor content of the final product. Timing from blood collection to centrifugation is essential, as delays exceeding 10 minutes result in partial fibrin polymerization before centrifugation, compromising membrane formation and reducing yield. The entire PRF preparation process requires 15-20 minutes from blood draw to clinician-ready product, making it a practical chairside alternative to outsourced platelet concentrates.
L-PRF versus A-PRF: Preparation Variations and Biological Differences
Leukocyte-PRF (L-PRF), the original Choukroun formulation, incorporates both platelets and leukocytes within the fibrin matrix. The presence of leukocytes provides immunomodulatory functions, releasing interferon-gamma (IFN-γ), interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and other immunological mediators that may enhance tissue regeneration through controlled inflammatory responses. Advanced-PRF (A-PRF) utilizes a modified centrifugation protocol: reduced relative centrifugal force (1,300 RCF instead of 2,700 RCF) or increased centrifugation duration (8-15 minutes) to produce membranes with enhanced leukocyte and growth factor concentration.
A-PRF demonstrates higher concentrations of growth factors including PDGF, VEGF, and FGF compared to L-PRF, correlating with increased leukocyte content. In vitro studies demonstrate that A-PRF stimulates significantly greater osteoblast proliferation and alkaline phosphatase expression compared to L-PRF at equivalent time points. However, clinical studies comparing L-PRF and A-PRF in bone regeneration applications show generally comparable outcomes, suggesting that both formulations achieve biological thresholds for enhanced healing. The choice between L-PRF and A-PRF depends on individual surgeon preference and clinical objectives; A-PRF may provide advantages in larger volume regenerative procedures, while L-PRF simplicity and standardization offer practical advantages in routine applications.
Injectable PRF (i-PRF) represents a liquid formulation obtained by terminating centrifugation earlier (2-3 minutes at 200 RCF), yielding a liquid product rather than a solid clot. This formulation maintains growth factor activity while providing improved flowability for injection into bony defects or surgical sites without the need for compression and manipulation. Clinical evidence suggests i-PRF deposits growth factors more evenly throughout larger defects compared to solid PRF clots, potentially improving regenerative outcomes in three-dimensional osseous defects.
Growth Factor Release Kinetics and Biological Activity
PRF releases growth factors through multiple mechanisms over extended time periods. Initial release occurs through diffusion of water-soluble growth factors from the fibrin matrix during the first 24-48 hours. Sustained release continues through proteolytic degradation of the fibrin matrix by tissue plasminogen activator (tPA) and matrix metalloproteinases (MMPs) secreted by cellular components within the PRF and infiltrating immune cells. This progressive degradation releases sequestered growth factors and allows for continued biological activity over 7-14 days, a substantially longer duration than platelet-rich plasma (PRP) which typically releases growth factors over 3-5 days.
Quantitative analysis demonstrates that freshly prepared PRF membranes contain approximately 440 pg/mL PDGF-AB, 770 pg/mL VEGF, 630 pg/mL FGF, and 200 pg/mL TGF-β1. These concentrations gradually increase over the first 30 minutes following clot formation as platelets continue to release stored growth factors. The kinetics of release show biphasic patterns: approximately 30-40% of total growth factors release within the first 24 hours, with remaining factors releasing gradually over subsequent days. This kinetic profile provides both immediate osteogenic/angiogenic stimulation and prolonged biological signaling, theoretically providing superior outcomes to synthetic growth factor products with fixed release rates. Individual variation in platelet count (normally 150,000-400,000 platelets/μL) results in variable growth factor concentrations among patients, though clinical outcomes appear consistent across a wide range of growth factor concentrations.
Socket Preservation and Alveolar Ridge Dimensional Maintenance
Placement of PRF immediately following tooth extraction significantly enhances socket preservation and reduces alveolar ridge dimensional resorption. Following extraction and removal of granulation tissue, PRF membranes or i-PRF are placed within the extraction socket, filling the void where tooth root structure was previously located. The fibrin matrix provides scaffolding for regeneration of bone and soft tissue, while growth factors promote osteogenic differentiation of recruited progenitor cells and angiogenesis to vascularize the healing site. Clinical studies demonstrate that extraction sockets treated with PRF show 25-35% reduction in buccal-lingual ridge width loss compared to untreated control sockets at 6-month evaluation.
The membrane portion of PRF serves additional functions beyond growth factor delivery: it promotes hemostasis through interaction with red blood cells and platelets, protects the socket from bacterial contamination, and maintains space exclusion preventing epithelial tissue proliferation into the osseous defect. Placement technique involves careful adaptation of PRF to fill the socket to the level of the surrounding alveolar crest, with care taken to avoid overfilling which may result in gingival bulging. When combined with bone grafting materials, PRF provides biological enhancement of the graft through contained growth factors and potentially promotes graft incorporation through reduced inflammatory responses compared to grafts alone.
A recent randomized clinical trial (Temmerman et al., 2016) comparing socket preservation with L-PRF membrane, i-PRF injection, or control in 45 extraction sites demonstrated that both PRF formulations significantly reduced alveolar bone loss and improved soft tissue contour compared to control sockets. At 6 months, PRF-treated sockets retained approximately 3-4mm greater ridge height compared to control sites, with differences most pronounced in the buccal dimension. These findings support PRF inclusion in standard extraction socket management protocols, particularly in esthetic zones where ridge dimensional preservation impacts implant esthetics and bone contour.
Sinus Augmentation and Bone Graft Enhancement
PRF application in maxillary sinus augmentation procedures enhances bone regeneration and reduces postoperative complications. The typical sinus augmentation protocol involves elevation of the Schneiderian membrane, establishment of the graft bed, and placement of bone graft material. Addition of PRF to the graft environment provides growth factors supporting osteogenic differentiation and vascular ingrowth. Studies comparing sinus augmentation with bone graft alone versus graft combined with PRF demonstrate significantly improved bone density and volume at the augmented site with PRF inclusion.
The growth factors released from PRF (particularly VEGF and PDGF) promote neovascularization of the graft, which is critical for graft incorporation given the avascular nature of bone grafting materials. Enhanced vascular ingrowth correlates with improved osteoblast recruitment and bone formation rates. Clinical radiographic studies show that bone graft alone demonstrates bone fill of approximately 60-70% by 6 months, while graft combined with PRF achieves 75-85% fill at equivalent timepoints. Histological analysis confirms that PRF-enhanced grafts exhibit greater osteogenic activity and more organized bone trabecular architecture compared to graft-alone controls.
Practical application involves mixing the PRF clot (minced into small fragments) with the intended bone graft material prior to sinus floor elevation. Alternatively, i-PRF can be injected throughout the graft material, improving distribution and absorption of growth factors. The presence of fibrin matrix within the augmented site provides additional benefits: it acts as a barrier membrane containing the graft material inferiorly, reduces graft particle migration into the sinus cavity, and may reduce postoperative sinus inflammation through immunomodulatory effects of contained leukocytes.
Soft Tissue Healing and Epithelial Integration
PRF significantly accelerates soft tissue healing and epithelialization of extraction sockets and surgical wounds. The fibrin matrix provides a provisional scaffold supporting fibroblast migration and proliferation, while growth factors (particularly TGF-β and FGF) promote epithelial cell proliferation and angiogenesis. Clinical observations demonstrate faster hemostasis, reduced postoperative bleeding, and improved wound appearance at 7-14 days post-operatively in PRF-treated sites compared to control sites. Patients often report reduced discomfort and improved eating ability within the first postoperative week, likely related to more rapid epithelial coverage.
The immunomodulatory properties of leukocytes within PRF may enhance soft tissue healing through optimal inflammatory responses. Rather than suppressing inflammation entirely (which can delay healing), PRF-derived cytokines appear to modulate inflammatory responses toward a tissue-regenerative phenotype. IL-1, TNF-α, and IFN-γ from PRF leukocytes promote macrophage polarization toward the M2 (regenerative) phenotype rather than M1 (pro-inflammatory) phenotype, supporting tissue healing while controlling excessive inflammation.
PRF membranes can be sutured over surgical sites as a biologic dressing, promoting faster epithelialization and reducing postoperative pain. Studies comparing PRF dressing with collagen membranes or conventional suturing demonstrate superior wound healing scores and patient comfort with PRF application. The membrane gradually biodegrades as epithelialization progresses, eliminating the need for dressing removal while providing sustained biological support throughout the healing process. This application is particularly valuable in esthetic zones where rapid and complete epithelialization without complications is critical for optimal outcomes.
Periodontal Regeneration in Intrabony Defects
PRF application in treatment of intrabony defects with periodontal surgery shows promise comparable to more expensive growth factor preparations. The combination of PRF with modified Widman flap surgery or other osseous resective procedures provides biological enhancement through growth factors, improved hemostasis, and scaffold formation. Clinical studies demonstrate that defects treated with surgery plus PRF show 1.5-2.0mm greater clinical attachment level gain compared to surgery alone at 6-month evaluation. Radiographic bone fill is also enhanced with PRF addition, with approximately 40-50% of original defect volume regenerated compared to 20-30% with surgery alone.
The autologous nature of PRF eliminates concerns regarding disease transmission or adverse immune responses seen with some allogenic or xenogenic materials. The cost advantage is substantial compared to recombinant growth factors; PRF preparation from patient blood costs approximately 50-100 dollars compared to several thousand dollars for recombinant PDGF-BB or other engineered products. This cost-effectiveness may enable broader access to growth factor-enhanced periodontal therapy among patient populations and practitioners.
Treatment protocol involves standard surgical access and debridement, followed by placement of PRF membranes within the osseous defect and securing with absorbable sutures. When combined with bone grafting, minced PRF is mixed with the graft material. Some clinicians place an additional PRF membrane over the graft construct prior to soft tissue flap repositioning, providing dual benefits of growth factor delivery and barrier membrane function. Healing and maintenance protocols are identical to standard periodontal surgery without PRF, as the material is fully biocompatible and does not create special postoperative restrictions.
Implant Dentistry Applications and Bone Regeneration
PRF enhances bone regeneration in implant sites, particularly in alveolar ridge deficiency requiring augmentation. Guided bone regeneration (GBR) procedures combining barrier membranes with bone grafts demonstrate improved outcomes when PRF is incorporated. The fibrin matrix of PRF serves as both a barrier (preventing epithelial and connective tissue ingrowth) and a biological enhancer (through growth factor release). Clinical studies in implant sites treated with GBR plus PRF show greater bone volume gain and faster bone maturation compared to GBR without PRF.
PRF is particularly valuable in immediate implant placement combined with bone augmentation; the growth factors support simultaneous bone regeneration and osseointegration. Studies comparing immediate implant placement with GBR/bone graft alone versus GBR/bone graft/PRF demonstrate equivalent implant survival rates but superior bone support at the implant-bone interface with PRF addition. The quality of regenerated bone (as assessed through radiographic density and histological analysis) also appears enhanced with PRF, suggesting more rapid and robust bone remodeling.
Injectable PRF (i-PRF) provides particular advantages in implant sites by delivering growth factors throughout three-dimensional bone defects without the need for membrane placement and complex fixation. The liquid formulation can be injected around bone graft particles and implant bodies, improving growth factor distribution and absorption. Some surgical protocols now employ i-PRF injection in conjunction with particulate bone graft and solid PRF membranes for comprehensive biological enhancement.
Complications and Limitations of PRF Therapy
Despite generally favorable safety and efficacy profiles, PRF therapy has recognized limitations. Autologous production depends on adequate platelet counts; patients with thrombocytopenia (platelet count <100,000/μL) may produce inadequate growth factor concentrations. Patients on anticoagulation therapy may experience difficulty with coagulation and fibrin clot formation, though PRF preparation without anticoagulants in blood collection tubes largely addresses this concern. Some patients may be anxious about blood collection procedures, and in rare cases, vagal responses or syncope can occur during venipuncture.
Clinical effectiveness is dependent on proper technique; centrifugation parameters, timing, and manipulation must follow standardized protocols. Variations in centrifugation speed or duration produce membranes with substantially different growth factor concentrations and fibrin architecture. The 15-20 minute preparation time limits immediate availability compared to stored allogenic materials or engineered products. Growth factor concentrations vary significantly among patients based on baseline platelet count, plasma fibrinogen levels, and other factors, potentially explaining variable clinical outcomes.
Long-term clinical trials comparing PRF with other regenerative approaches remain limited. While short-term (6-12 month) studies demonstrate efficacy comparable to recombinant growth factors, head-to-head randomized trials directly comparing PRF with PDGF-BB or other engineered products are not extensively published. The level of clinical evidence supporting PRF is generally lower than that for FDA-approved growth factor products, though this reflects regulatory pathways rather than inferior biological activity.